Navigation Links
ACTEMRA(R) (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies
Date:6/13/2008

- Phase III monotherapy study shows ACTEMRA is first and only biologic to demonstrate statistical superiority over methotrexate after 24 weeks of

treatment -

PARIS, June 13 /PRNewswire/ -- Patients who suffer the chronic and debilitating effects of rheumatoid arthritis (RA) -- despite treatment with current therapies -- achieved significant improvements in signs and symptoms when treated with Roche's ACTEMRA(R) (tocilizumab) alone or in combination with methotrexate compared with methotrexate alone, according to two international Phase III studies presented by researchers at the European Congress of Rheumatology (ECR) held by the European League Against Rheumatism (EULAR) in Paris.

Data from two new Phase III studies -- RADIATE and AMBITION trials -- will be highlighted as oral presentations at the congress, along with 21 additional abstracts involving ACTEMRA, a novel interleukin-6 (IL-6) receptor inhibitor being studied for the treatment of moderate to severe RA. Importantly, findings from the RADIATE study were also published online this week in the Annals of the Rheumatic Diseases.

In the RADIATE study, which evaluated difficult-to-treat patients who failed to respond to prior anti-TNF therapies, 50 percent of ACTEMRA-treated patients achieved a 20 percent (ACR20(1)) reduction in signs and symptoms. The AMBITION study showed that significantly more patients receiving ACTEMRA achieved a 20 percent improvement in their signs and symptoms [ACR20: 70%]. No previous biologic therapy has demonstrated statistically significant superiority compared to methotrexate in this important clinical parameter at week 24. In addition, nearly one-third of all ACTEMRA patients from both studies reached disease remission (as defined by DAS28 <2.6(2)).

"We are very encouraged by the results of the AMBITION study that shows for the first time that treatment with a single biologic agent is superior to methotrexate at s
'/>"/>

SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
2. New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients
3. Two Pivotal Phase III Studies for Roches ACTEMRA(TM) (tocilizumab) Demonstrate Significant Improvement in Rheumatoid Arthritis Symptoms
4. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
5. DEFLUX(R) Significantly Reduces Urinary Tract Infections in Children With Vesicoureteral Reflux
6. Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS)
7. Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
8. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
9. New Data Reveal Topical Divigel(R) (estradiol gel) 0.1% Significantly Reduces Frequency and Severity of Hot Flashes
10. Promising Phase 3 Trial Results Show Novel Biologic Therapy Ustekinumab (CNTO 1275) Significantly Improved Psoriasis
11. INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)...  Research and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) has announced the ... Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) ... in order to treat dental impairments, for tooth restoration ...
(Date:1/15/2014)... IRVING, Texas , Jan. 15, 2014  Novation, the ... company, awarded several new IT value-added reseller (VAR) national ... with IT goods and services at lower costs. These ... value-added services such as initiative assistance and ongoing IT ...
(Date:1/15/2014)... 2014 Shire plc (LSE: SHP, NASDAQ: ... Trading (OFT) approval condition to the announced tender offer for all ... As a result of the waiver, the transaction is no ... tender offer on January 24, 2014 following the currently scheduled expiration ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
... Pharmaceuticals, Inc. (Nasdaq: CADX ) today announced that ... of its common stock at a price to the public ... of the shares, after deducting the underwriting discounts and commissions ... million.  Cadence has granted the underwriters for the offering a ...
... NEW YORK, Nov. 15, 2011 Reportlinker.com ... is available in its catalogue: ... East Asia ... analysis of four pharmaceutical markets that present ...
Cached Medicine Technology:Cadence Pharmaceuticals Announces Pricing of Public Offering of Common Stock 2Cadence Pharmaceuticals Announces Pricing of Public Offering of Common Stock 3The Outlook for Pharmaceuticals in North East Asia 2The Outlook for Pharmaceuticals in North East Asia 3The Outlook for Pharmaceuticals in North East Asia 4
(Date:4/18/2014)... one of your worst memories? How did it make ... during a negative personal experience, such as how sad ... to emotional distress, especially when you can,t stop thinking ... up, thinking about the context of the memories, rather ... effective way to alleviate the negative effects of these ...
(Date:4/18/2014)... Fraser University psychologists have made a brain-related discovery ... attention-deficit disorders. , This discovery opens up the ... or suppress a specific brain activity that the ... , The Journal of Neuroscience has ... John McDonald, an associate professor of psychology and ...
(Date:4/18/2014)... . A ... A team led by Ludwik Leibler from the Laboratoire ... Letourneur from the Laboratoire Recherche Vasculaire Translationnelle (INSERM/Universits Paris ... principle of adhesion by aqueous solutions of nanoparticles can ... tissues. This easy-to-use gluing method has been tested on ...
(Date:4/17/2014)... in benign prostate tissue was associated with high-grade, ... found even in those with low prostate-specific antigen ... Cancer Epidemiology, Biomarkers & Prevention , a ... , An analysis of prostate tissue biopsies collected ... the Prostate Cancer Prevention Trial (PCPT) found that ...
(Date:4/17/2014)... first genetic variant specifically associated with the risk ... 10-15 per cent of all breast cancer cases. ... cancer sub-type, called invasive lobular carcinoma, gives researchers ... particular kind of breast cancer, which can be ... (Thursday) in the journal PloS Genetics , ...
Breaking Medicine News(10 mins):Health News:New study suggests a better way to deal with bad memories 2Health News:New study suggests a better way to deal with bad memories 3Health News:Scientists discover brain's anti-distraction system 2Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3
... Nov. 26 David B. Snow,chairman & chief executive ... to address the Merrill Lynch & Co., Inc. 2007 ... presentation at Merrill Lynch headquarters, New York, will begin ... and Richard J.,Rubino, CPA, Medco,s controller and chief accounting ...
... CHICAGO, Nov. 26 All-terrain vehicles (ATVs) pose a,serious ... largest study ever,conducted of ATV injuries in children. The ... Radiological Society of North America (RSNA)., "Our experience ... be restricted," said Chetan C. Shah, M.D., radiology fellow ...
... women have a different understanding of screening mammography ... the findings of a Boston University Medical Center ... the Radiological Society of North America (RSNA). , ... ethnic and socioeconomic groups, said Nazia F. Jafri, ...
... PHILADELPHIA Researchers at the University of Pennsylvania School ... transcranial magnetic stimulation (TMS) a non-invasive technique that ... through the scalp is a safe and effective, ... major depression who have tried other treatment options without ...
... and its there in bright medical images: evidence of ... secondhand cigarette smoke. For the first time, researchers have ... but not previously detectable with medical imaging tools. ... public health efforts to restrict secondhand smoke. , ...
... FAAN, FAHA, a clinical professor of neurology at Boston ... the Framingham Heart Study, was recently awarded the Stroke ... award was presented at the AHAs recent Scientific Sessions ... Award recognizes and encourages those who actively work to ...
Cached Medicine News:Health News:Medco CEO to Present at the Merrill Lynch & Co., Inc. 2007 Health Services Investor Conference 2Health News:Injury Report Shows All-Terrain Vehicles Not Child's Play 2Health News:Injury Report Shows All-Terrain Vehicles Not Child's Play 3Health News:Attitudes toward mammography differ across ethnicities, cultures, backgrounds 2Health News:Penn research shows transcranial magnetic stimulation effective in treating major depression 2Health News:Secondhand smoke damages lungs, MRIs show 2
... and removal in the urinary tract. The nitinol ... shape following extreme torsion. The unique tipless design ... basket to open at the base of the ... reduces the likelihood of mucosal damage and perforation. ...
... Filiform Spiral Tip 12 Inch , 20 ... female thread. Available in 3,4,5 6Fr. These ... strong but flexible polymer material and have ... other brands. They are manufactured to the ...
... for stone manipulation and removal in the urinary ... Delta Wire. The revolutionary triangular shape of Delta ... largest possible wire mass. The superior mass of ... qualities of nitinol alloy, creates a basket with ...
... SILASTIC Brand Latex Foley Catheter, Smooth, ... build-up, Firm, but flexible, latex-based construction ... length - round tip with two ... (336xx) or two staggered eyes and ...
Medicine Products: